Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR1018B + BR1018C
- Development stage
- Unknown
- Lead developer
- Boryung
- Administration
- Oral
01
Overview
A fixed combination treatment under development for **essential hypertension**, composed of two agents referred to by the codenames **BR1018B** and **BR1018C**. Both agents are being clinically investigated together as combination therapy in late-phase trials targeting blood pressure reduction, with endpoints focused on mean sitting systolic blood pressure and LDL-C. While the precise molecular identity and mechanism for each code-named agent have not been disclosed publicly in the clinical registries or product literature, the combination is being studied for its efficacy and safety profile specifically for patients with essential hypertension[3][5][7].
Beyond the preview
Go deeper on BR1018B + BR1018C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR1018B + BR1018C.